A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10 percent (IGIV, 10 percent) for the Treatment of Mild to Moderate Alzheimer's Disease.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10 percent (IGIV, 10 percent) for the Treatment of Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GAP
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 05 Apr 2017 Results assessing safety and efficacy of Immune-globulin in ITT population and subgroups, published in the Neurology
    • 16 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
    • 16 Jul 2013 Positive data from cognition and biomarker tests presented at the Alzheimer's Association International Conference 2013 (AAIC 2013), according to a Baxter International media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top